400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / TGF-beta/Smad / PKC / Staurosporine/星形孢菌素
CAS No.: 62996-74-1
Synonyms: Antibiotic AM-2282;STS;AM-2282
Staurosporine is a prototypical potent ATP-competitive multikinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.
生物活性
靶点 | CaMKII IC50:20nM | PKA IC50:7nM | PKC IC50:0.7nM | PKG IC50:8.5nM | v-Src (p60) IC50:6nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00651261 | Leukemia | Phase 3 | Active, not recruiting | - | - |
NCT01161550 | Leukemia, Myeloid, Acute | Phase 1 | Completed | - | United States, Missouri ... more >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 Collapse << |
NCT00019838 | Leukemia Lymp... more >>homa Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Collapse << |
实验方案
技术信息
CAS号 | 62996-74-1 | 储存条件 |
|
|||||||||||||
分子式 | C28H26N4O3 | 运输 | 蓝冰 | |||||||||||||
分子量 | 466.53 | 别名 | Antibiotic AM-2282;STS;AM-2282;CGP 41251;Stsp;Antibiotic 230;CCRIS 3272;Staurosporin;星形孢菌素 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
FL5.12-Akt1 cells | - | Proliferation assay | - | Antiproliferative activity against FL5.12-Akt1 cells by MTT assay, IC50=0.29 μM. | 16403626 |
HEK293 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay, IC50=56 nM. | 24763262 |
HEK293 cells | - | Function assay | - | Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2, IC50=77 nM. | 15771419 |
HEK293 cells | - | Cytotoxic assay | - | Cytotoxicity against HEK293 cells, EC50=2 μM. | 25316317 |
HUE cells | - | Function assay | 90 mins | Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA, IC50=70 nM. | 20170163 |
human 518A2 cells | - | Cytotoxic assay | 96 h | Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay, IC50=0.2 μM. | 24361521 |
human 8505C cells | - | Cytotoxic assay | 96 h | Cytotoxicity against human 8505C cells after 96 hrs by SRB assay, IC50=0.2 μM. | 24361521 |
human A2780 cells | - | Cytotoxic assay | 96 h | Cytotoxicity against human A2780 cells after 96 hrs by SRB assay, IC50=0.2 μM. | 24361521 |
human A431 cells | - | Cytotoxic assay | 24 h | Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay, IC50=70 nM. | 22541051 |
human A549 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method | 18484775 |
human A549 cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human A549 cells after 48 hrs by MTT assay , IC50=20 nM. | 25825934 |
human A549 cells | - | Cytotoxic assay | 96 h | Cytotoxicity against human A549 cells after 96 hrs by SRB assay, IC50=0.6 μM. | 24361521 |
human BGC823 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.38 μM. | 24328283 |
human BJ cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay, IC50=0.002 μM. | 22921081 |
human BJ cells | - | Cytotoxic assay | - | Cytotoxicity against human BJ cells, EC50=2 μM. | 25316317 |
human CEM cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay, IC50=23 nM. | 22921081 |
human CHOK1 cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay, IC50=0.13 μM. | 21513294 |
human colon cancer cell line (LoVo cells) | - | Proliferation assay | - | Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay, IC50=0.001 μM. | 11591505 |
human colon carcinoma cell line HCT116 | - | Function assay | - | Concentration required for growth inhibition of human colon carcinoma cell line HCT116, IC50=6 nM. | 15537345 |
human DLD1 cells | - | Proliferation assay | 48-72 h | Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay, IC50=9 nM. | 22182929 |
human HeLa cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50=4e-06 μM. | 21388191 |
human HeLa cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50=25 nM. | 25825934 |
human HepG2 cells | - | Cytotoxic assay | - | Cytotoxicity against human HepG2 cells, EC50=2 μM. | 25316317 |
human HT-29 cells | - | Function assay | 2 h | Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay | 21428375 |
human HT-29 cells | - | Function assay | - | Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay, IC50=2.5 nM | 21513293 |
human HT-29 cells | - | Function assay | 2 h | Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay, EC50=2.6 nM. | 21973101 |
human HuH7 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.23 μM. | 24328283 |
human HUVEC | - | Proliferation assay | 48 to 72 h | Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay | 22182929 |
human Jurkat cells | - | Proliferation assay | - | Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells, IC50=71 nM. | 19427203 |
human KE-97 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human KE-97 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.13 μM. | 24328283 |
human LoVo cells | - | Proliferation assay | 48 to 72 h | Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay | 22182929 |
human MCF7 cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=50 nM. | 21388191 |
human MCF7 cells | - | Cytotoxic assay | 96 h | Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay, IC50=0.4 μM. | 24361521 |
human MDA-MB-231 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method, GI50=7.1 nM. | 18484775 |
human MiaPaCa-2 cells | - | Proliferation assay | - | Antiproliferative activity against human MiaPaCa-2 cells, IC50=0.37 μM. | 16413780 |
human PBMC | - | Function assay | 24 h | Suppression of IL2 production in human PBMC after 24 hrs by ELISA, IC50=16 nM. | 18585046 |
human PC3 cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human PC3 cells after 48 hrs by MTT assay , IC50=31 nM. | 25825934 |
human Raji cells | - | Cytotoxic assay | - | Cytotoxicity against human Raji cells, EC50=2 μM. | 25316317 |
human SF268 cells | - | Cytotoxic assay | 48 h | Cytotoxicity against human SF268 cells after 48 hrs by SRB assay, GI50=44 nM. | 21513294 |
human ST486 cells | - | Proliferation assay | 48 to 72 h | Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay, IC50=7 nM. | 22182929 |
human U937 cells | - | Cytotoxic assay | - | Cytotoxicity against human U937 cells, IC50=2 μM. | 17088067 |
insect cells | - | Function assay | - | Inhibition of human recombinant Pim1 expressed in insect cells by HTRF, IC50=10 nM. | 19179076 |
mouse NIH/3T3 cells | - | Cytotoxic assay | 96 h | Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, IC50=0.2 μM. | 24361521 |
P19 cells | - | Function assay | - | Inhibition of Platelet-derived growth factor receptor in P19 cells, IC50=0.002 μM. | 15771419 |
P19 cells | - | Function assay | - | Inhibition of Protein Kinase A in P19 cells, IC50=4 nM. | 15771419 |
P19 cells | - | Function assay | - | Inhibition of Cyclin-dependent kinase 1 in P19 cells, IC50=8 nM. | 15771419 |
P19 cells | - | Function assay | - | Inhibition of Vascular endothelial growth factor receptor in P19 cells, IC50=14 nM. | 15771419 |
Sf21 cells | - | Function assay | - | Inhibition of JAK3 expressed in Sf21 cells, IC50=6 nM. | 17088059 |
Sf9 cells | - | Function assay | - | Inhibition of human Syk expressed in Sf9 cells, IC50=3 nM. | 18823784 |
Sf9 cells | - | Function assay | - | Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP | 17315853 |
Sf9 cells | - | Function assay | 20 mins | Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP, IC50=15 nM. | 17315853 |
V79 MZ cells | - | Function assay | - | Inhibition of human aldosterone synthase expressed in V79 MZ cells assessed as inhibition of aldosterone synthesis, IC50=11 nM. | 24422519 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00651261 | Leukemia | Phase 3 | Active, not recruiting | - | - |
NCT01161550 | Leukemia, Myeloid, Acute | Phase 1 | Completed | - | United States, Missouri ... more >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 Collapse << |
NCT00019838 | Leukemia Lymp... more >>homa Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Collapse << |
NCT00651261 | - | - | Active, not recruiting | - | - |
NCT02115295 | Leukemia | Phase 2 | Recruiting | May 2019 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse << |
NCT01754441 | - | - | Unknown | December 2017 | United States, Delaware ... more >> Alfred I. duPont Hospital for Children Wilmington, Delaware, United States, 19803 United States, Florida Nemours Children's Specialty Care, Jacksonville Jacksonville, Florida, United States, 32207 Nemours Children's Hospital Orlando, Florida, United States, 32827 Collapse << |
NCT03512197 | Acute Myeloid Leukemia (AML) | Phase 3 | Recruiting | April 20, 2026 | - |
NCT03092674 | Acute Myeloid Leukemia ... more >> Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts-2 Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 2 Phase 3 | Suspended(Other - Safety data ... more >>review, unscheduled) Collapse << | August 1, 2023 | - |
NCT03591510 | FLT3-mutated Acute Myeloid Leu... more >>kemia Collapse << | Phase 2 | Not yet recruiting | April 21, 2025 | Korea, Republic of ... more >> Novartis Investigative Site Seoul, Korea, Republic of, 03080 Collapse << |
NCT00042861 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Collapse << |
NCT00031681 | Advanced Adult Primary Liver C... more >>ancer Carcinoma of the Appendix Estrogen Receptor-negative Breast Cancer Extensive Stage Small Cell Lung Cancer Gastrointestinal Stromal Tumor HER2-negative Breast Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Sarcoma Ovarian Stromal Cancer Progesterone Receptor-negative Breast Cancer Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Adult Primary Liver Cancer Recurrent Anal Cancer Recurrent Basal Cell Carcinoma of the Lip Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor Recurrent Breast Cancer Recurrent Cervical Cancer Recurrent Colon Cancer Recurrent Endometrial Carcinoma Recurrent Esophageal Cancer Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Gastrointestinal Carcinoid Tumor Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Lymphoepithelioma of the Nasopharynx Recurrent Lymphoepithelioma of the Oropharynx Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Recurrent Mucoepidermoid Carcinoma of the Oral Cavity Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Prostate Cancer Recurrent Rectal Cancer Recurrent Salivary Gland Cancer Recurrent Small Cell Lung Cancer Recurrent Small Intestine Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Small Intestine Adenocarcinoma Small Intestine Leiomyosarcoma Small Intestine Lymphoma Stage IV Adenoid Cystic Carcinoma of the Oral Cavity Stage IV Anal Cancer Stage IV Basal Cell Carcinoma of the Lip Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor Stage IV Breast Cancer Stage IV Colon Cancer Stage IV Endometrial Carcinoma Stage IV Esophageal Cancer Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Stage IV Gastric Cancer Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Stage IV Lymphoepithelioma of the Nasopharynx Stage IV Lymphoepithelioma of the Oropharynx Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Stage IV Mucoepidermoid Carcinoma of the Oral Cavity Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Prostate Cancer Stage IV Rectal Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Stage IVA Cervical Cancer Stage IVB Cervical Cancer Triple-negative Breast Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer Unspecified Adult Solid Tumor, Protocol Specific Untreated Metastatic Squamous Neck Cancer With Occult Primary Collapse << | Phase 1 | Completed | - | United States, Virginia ... more >> University of Virginia Charlottesville, Virginia, United States, 22908 Collapse << |
NCT00045513 | Leukemia Lymp... more >>homa Collapse << | Phase 1 Phase 2 | Completed | - | Canada, Ontario ... more >> McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario, Canada, L8N 3Z5 London Health Sciences Centre London, Ontario, Canada, N6A 465 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00045942 | - | - | Completed | - | - |
NCT00819546 | Acute Myeloid Leukemia ... more >> Myelodysplastic Syndrome Collapse << | Phase 1 | Active, not recruiting | December 2019 | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Collapse << |
NCT00047242 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 Collapse << |
NCT01477606 | Acute Myeloid Leukemia | Phase 2 | Active, not recruiting | June 2020 | - |
NCT03280030 | Acute Myeloid Leukemia | Phase 2 | Recruiting | June 20, 2022 | Hong Kong ... more >> Novartis Investigative Site Recruiting Hong Kong, Hong Kong Japan Novartis Investigative Site Recruiting Nagoya-city, Aichi, Japan, 466-8650 Novartis Investigative Site Recruiting Toyoake city, Aichi, Japan, 470 1192 Novartis Investigative Site Recruiting Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Recruiting Matsuyama-city, Ehime, Japan, 790-8524 Novartis Investigative Site Recruiting Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Fukuyama city, Hiroshima, Japan, 720-0001 Novartis Investigative Site Recruiting Isehara-city, Kanagawa, Japan, 259-1193 Novartis Investigative Site Recruiting Kochi city, Kochi, Japan, 781-8555 Novartis Investigative Site Recruiting Nagasaki-city, Nagasaki, Japan, 852-8501 Novartis Investigative Site Recruiting Sayama, Osaka, Japan, 589 8511 Novartis Investigative Site Recruiting Shimotsuke city, Tochigi, Japan, 329-0498 Novartis Investigative Site Recruiting Bunkyo-ku, Tokyo, Japan, 113-8677 Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Korea, Republic of Novartis Investigative Site Recruiting Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Recruiting Putzu City, Chiayi Hsien, Taiwan, 61363 Novartis Investigative Site Recruiting Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Recruiting Taipei, Taiwan, 10002 Novartis Investigative Site Recruiting Taoyuan, Taiwan, 33305 Collapse << |
NCT00093600 | Acute Myeloid Leukemia (AML) | Phase 1 | Completed | - | United States, California ... more >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 United States, Massachusetts Dana Faber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201-2014 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 Germany Novartis Investigative Site Dresden, Germany Novartis Investigative Site Mainz, Germany Collapse << |
NCT00045942 | Acute Myeloid Leukemia ... more >> Myelodysplastic Syndromes Collapse << | Phase 1 Phase 2 | Completed | - | United States, California ... more >> UCLA Medical Center Los Angeles, California, United States, 90095 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York New York Weill Cornell Medical Center New York, New York, United States, 10021 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT03760445 | Leukemia, Myeloid, Acute | Phase 1 Phase 2 | Not yet recruiting | October 13, 2022 | - |
NCT00036777 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Collapse << |
NCT01130662 | Acute Myeloid Leukemia | Phase 1 | Completed | - | United States, Kansas ... more >> University of Kansas Medical Center, Westwood Campus Kansas City, Kansas, United States, 66205 Collapse << |
NCT00012194 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Terminated | - | United States, New Hampshire ... more >> Dartmouth Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 Collapse << |
NCT00045175 | Fallopian Tube Cancer ... more >> Ovarian Cancer Primary Peritoneal Cavity Cancer Collapse << | Phase 1 | Completed | - | Canada, Ontario ... more >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00039403 | Adenocarcinoma of the Pancreas... more >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Collapse << | Phase 1 | Completed | - | United States, Texas ... more >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT03258931 | Newly Diagnosed FLT3 Mutated A... more >>ML Collapse << | Phase 3 | Recruiting | November 2024 | United States, California ... more >> US Davis Health Recruiting Sacramento, California, United States, 95817 Contact: Brian Jonas, MD 800-282-3284 bajonas@ucdavis.edu United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Kendra Sweet, MD 813-745-6841 Kendra.Sweet@moffitt.org United States, Kansas University of Kansas Recruiting Kansas City, Kansas, United States, 66160 Contact: Sunil Abhyankar, MD 913-588-9281 sabhyankar@kumc.edu United States, Massachusetts Dana-Farber Cancer Insitute Recruiting Boston, Massachusetts, United States, 02215 Contact: Richard M Stone, MD 617-632-2214 Richard_Stone@dfci.harvard.edu United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jay Yang, MD 800-527-6266 yangj@karmanos.org Henry Ford Health System Recruiting Detroit, Michigan, United States, 48202 Contact: Yue Guo, MD 800-436-7936 YGUO1@hfhs.org United States, New York Roswell PArk Recruiting Buffalo, New York, United States, 14263 Contact: Eunice S Wang, MD 716-845-3544 eunice.wang@roswellpark.org Collapse << |
NCT00045500 | Lymphoma Unsp... more >>ecified Adult Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Frederick Cancer Research and Development Center Frederick, Maryland, United States, 21702-1201 Collapse << |
NCT00006464 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, California ... more >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 City of Hope Medical Group Pasadena, California, United States, 91105 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, New Hampshire Norris Cotton Cancer Center Lebanon, New Hampshire, United States, 03756-0002 Collapse << |
NCT00045747 | Pancreatic Cancer | Phase 2 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00004059 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00072267 | Fallopian Tube Cancer ... more >> Ovarian Cancer Primary Peritoneal Cavity Cancer Collapse << | Phase 2 | Completed | - | Canada, Ontario ... more >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00098956 | Extensive Stage Small Cell Lun... more >>g Cancer Recurrent Small Cell Lung Cancer Collapse << | Phase 2 | Completed | - | Canada, Ontario ... more >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00098956 | - | - | Completed | - | - |
NCT03207334 | Acute Myeloid Leukemia | Phase 2 | Withdrawn(Insufficient funding... more >>) Collapse << | January 2022 | United States, Florida ... more >> University of Florida Gainesville, Florida, United States, 32610 Collapse << |
NCT01202877 | - | - | Completed | - | - |
NCT00030888 | Kidney Cancer | Phase 2 | Unknown | - | United States, California ... more >> UCSF Comprehensive Cancer Center San Francisco, California, United States, 94115 Veterans Affairs Medical Center - San Francisco San Francisco, California, United States, 94121 Collapse << |
NCT00004263 | Leukemia Myel... more >>odysplastic Syndromes Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Texas University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00072189 | Recurrent Melanoma ... more >> Stage IV Melanoma Collapse << | Phase 2 | Terminated(Early termination f... more >>or discouraging results) Collapse << | - | United States, California ... more >> UC Davis Cancer Center Sacramento, California, United States, 95817 Collapse << |
NCT01174888 | Acute Myeloid Leukemia ... more >> Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> The Ohio State University Medical Center Columbus, Ohio, United States, 43210 Collapse << |
NCT00072189 | - | - | Terminated(Early termination f... more >>or discouraging results) Collapse << | - | - |
NCT00082017 | Lymphoma, Large-Cell, Ki-1 ... more >> Lymphoma, T-Cell Collapse << | Phase 2 | Terminated(IND was withdrawn b... more >>y CTEP due to low accrual and cost of maintaining the IND.) Collapse << | - | United States, Maryland ... more >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Collapse << |
NCT00233454 | Systemic Mastocytosis, Aggress... more >>ive (ASM) Leukemia, Mast Cell Hematological Non-mast Cell Lineage Disease (AHNMD) Collapse << | Phase 2 | Completed | - | United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University-St. Louis Saint Louis, Missouri, United States, 63110 Collapse << |
NCT01202877 | Leukemia | Phase 1 Phase 2 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00003289 | Leukemia Lymp... more >>homa Unspecified Adult Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Johns Hopkins Oncology Center Baltimore, Maryland, United States, 21231 Collapse << |
NCT00301938 | Accelerated Phase Chronic Myel... more >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Collapse << |
NCT00782067 | Leukemia | Phase 2 | Completed | - | - |
NCT00782067 | - | - | Completed | - | - |
NCT01282502 | Adenocarcinoma of the Rectum | Phase 1 | Completed | - | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Collapse << |
NCT00082017 | - | - | Terminated(IND was withdrawn b... more >>y CTEP due to low accrual and cost of maintaining the IND.) Collapse << | - | - |
NCT00866281 | Acute Myeloid Leukemia ... more >> Acute Lymphoblastic Leukemia Collapse << | Phase 1 Phase 2 | Terminated(Despite considerabl... more >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) Collapse << | - | United States, Washington ... more >> Seattle Children's Hospital CPKC412A2114 Seattle, Washington, United States, 98105 France Novartis Investigative Site Paris Cedex 19, France, 75935 Italy Novartis Investigative Site Genova, GE, Italy, 16147 Novartis Investigative Site Monza, MB, Italy, 20900 Novartis Investigative Site Roma, RM, Italy, 00165 Novartis Investigative Site Torino, TO, Italy, 10126 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3015 GJ Sweden Novartis Investigative Site Stockholm, Sweden, SE-171 76 Collapse << |
NCT00866281 | - | - | Terminated(Despite considerabl... more >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) Collapse << | - | - |
NCT01830361 | Acute Myeloid Leukemia | Phase 2 | Active, not recruiting | September 2020 | Germany ... more >> Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III Chemnitz, Germany Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I Dresden, Germany Marien Hospital Düsseldorf, Germany Universitätsklinikum Erlangen, Medizinische Klinik 5 Erlangen, Germany Klinikum der Johann-Wolfgang-Goethe Universität Frankfurt Main, Germany Universitätsklinikum Heidelberg Heidelberg, Germany Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany Universitätsklinikum Gießen und Marburg GmbH Marburg, Germany Universitätsklinikum Münster Münster, Germany Städtisches Klinikum Nord Nürnberg, Germany Klinikum der Universität Regensburg Regensburg, Germany Collapse << |
NCT01883362 | Acute Myeloid Leukemia | Phase 2 | Completed | - | - |
NCT01429337 | Hepatic Impairment | Phase 1 | Recruiting | August 14, 2019 | United States, Texas ... more >> Novartis Investigator site Not yet recruiting Houston, Texas, United States, 77030 Novartis Investigator site Not yet recruiting San Antonio, Texas, United States, 78215 Belgium Novartis Investigative Site Terminated Bruxelles, Belgium, 1200 Bulgaria Novartis Investigative Site Recruiting Sofia, Bulgaria, 1618 Germany Novartis Investigative Site Terminated Berlin, Germany, 14050 Novartis Investigative Site Terminated Frankfurt, Germany, 60590 Lithuania Novartis Investigator site Not yet recruiting Kaunas, Lithuania, LT-50161 Poland Novartis Investigative Site Terminated Warszawa, Poland, 02 106 Romania Novartis Investigative Site Recruiting Cluj, Napoca, Romania, 400006 Collapse << |
NCT02078609 | AML and High Risk MDS | Phase 1 | Recruiting | September 3, 2019 | United States, Michigan ... more >> Novartis Investigative Site Recruiting Ann Arbor, Michigan, United States, +1 48109 0944 Contact: Sabrina Pelton Hargrove +1 734 936 8538 sgomes@med.umich.edu Principal Investigator: Dale Bixby United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Recruiting Prahran, Victoria, Australia, 3181 France Novartis Investigative Site Completed Marseille, France, 13273 Germany Novartis Investigative Site Completed Ulm, Germany, 89081 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20132 Novartis Investigative Site Recruiting Milano, MI, Italy, 20162 Novartis Investigative Site Recruiting Roma, RM, Italy, 00133 Japan Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Netherlands Novartis Investigative Site Recruiting Amsterdam, Netherlands, 1081 HV Collapse << |
NCT01920204 | Indolent Systemic Mastocytosis | Phase 2 | Unknown | May 2015 | Netherlands ... more >> University Medical Center Groningen Groningen, Netherlands, 9700RB Collapse << |
NCT02634827 | Acute Myeloid Leukemia With FL... more >>T3/ITD Mutation Acute Myeloid Leukemia With Gene Mutations FLT3 Tyrosine Kinase Domain Point Mutation Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 2 | Active, not recruiting | April 15, 2020 | United States, Minnesota ... more >> Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << |
NCT03114228 | - | - | - | - | Canada, Ontario ... more >> Novartis Investigative Site Hamilton, Ontario, Canada, L8V 1C3 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 Collapse << |
NCT00233454 | - | - | Completed | - | - |
NCT03686345 | Core Binding Factor Acute Myel... more >>oid Leukemia (CBF-AML) Collapse << | Phase 2 | Active, not recruiting | December 31, 2025 | Italy ... more >> Ospedale Cà Granda - Niguarda S.C: Ematologia Milano, Italy, 20162 Collapse << |
NCT02723435 | Acute Myeloid Leukemia With Ge... more >>ne Mutations Adult Acute Myeloid Leukemia in Remission Collapse << | Phase 2 | Withdrawn(Logistical and admin... more >>istrative issues) Collapse << | - | - |
NCT02624570 | - | - | - | - | - |
NCT03379727 | Acute Myeloid Leukemia | Phase 3 | Recruiting | December 30, 2021 | - |
NCT00001444 | Breast Cancer ... more >> Lymphoma Neoplasm Prostatic Neoplasm Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Collapse << |
NCT01846624 | Acute Myeloid Leukemia (AML) W... more >>ith Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults AML (Adult) With 11q23 (MLL) Abnormalities AML (Adult) With Del (5q) AML (Adult) With Inv (16) (p13; q22) AML (Adult) With t (16;16) (p13; q22) AML (Adult) With t (8; 21) (q22; q22) Secondary AML (Adult) Untreated AML (Adult) Collapse << | Phase 2 | Terminated(Accrual factor) | - | United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 Collapse << |
NCT01846624 | - | - | Terminated(Accrual factor) | - | - |
NCT01093573 | Untreated Adult Acute Myeloid ... more >>Leukemia Collapse << | Phase 1 Phase 2 | Unknown | - | United States, Ohio ... more >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 Collapse << |
靶点 | Description | IC50 |
---|---|---|
CaMKII | IC50:20nM | |
PKA | IC50:7nM | |
PKC | IC50:0.7nM | |
PKG | IC50:8.5nM | |
v-Src (p60) | IC50:6nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网